Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATACAND vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Treatment of hypertension,Treatment of heart failure (NYHA class II-IV and left ventricular systolic dysfunction) to reduce cardiovascular death and hospitalization for heart failure
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Candesartan is primarily metabolized by ester hydrolysis to its active metabolite, candesartan, and further undergoes O-deethylation by CYP2C9 (minor route).
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
High protein binding: >99%, primarily to serum albumin.
10-25% bound to albumin at therapeutic concentrations.
Volume of distribution (Vd) is approximately 0.13 L/kg (mean 9 L). This low Vd indicates limited extravascular distribution, consistent with high plasma protein binding.
0.8-1.0 L/kg. Indicates distribution into total body water.
Absolute oral bioavailability is approximately 15% (prodrug candesartan cilexetil is completely converted to active candesartan during absorption). Food does not affect bioavailability.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
No initial dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min (including dialysis), initiate at 4 mg once daily and titrate cautiously with monitoring.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
For Child-Pugh Class A or B: initiate at 4 mg once daily and titrate cautiously. Child-Pugh Class C: not recommended (no data).
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
For children ≥1 year and <6 years: 0.2-0.4 mg/kg/day once daily or divided twice daily; maximum 0.6 mg/kg/day (up to 32 mg/day). For children ≥6 years: 4-8 mg once initially; may increase to 16 mg once daily (or 32 mg daily in larger children).
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Start at 4 mg once daily in patients ≥75 years; adjust based on blood pressure response and renal function (e.g., GFR <30 m L/min).
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
When pregnancy is detected, discontinue ATACAND as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Hypotension: Symptomatic hypotension may occur in volume-depleted patients or those with heart failure.,Hyperkalemia: Monitor serum potassium, especially in patients with renal impairment or on potassium-sparing diuretics.,Renal impairment: Use caution in patients with renal artery stenosis or severe renal impairment; monitor renal function.,Fetal/neonatal morbidity and mortality: As noted in black box warning.,Avoid use in patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hypersensitivity to candesartan or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
No significant food interactions. Avoid potassium-rich foods (e.g., bananas, oranges, spinach, avocados) in large amounts if also taking potassium supplements or potassium-sparing diuretics. Salt substitutes containing potassium chloride should be used cautiously.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects, hypotension, anuria) due to direct renin-angiotensin system blockade. Risk of neonatal renal failure and hypotension if exposed after 20 weeks gestation.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
No data on candesartan in human milk; animal studies detect drug in milk. M/P ratio unknown. Avoid breastfeeding due to potential risk of neonatal hypotension and renal impairment.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Avoid use in second and third trimesters due to fetotoxicity. If inadvertent exposure occurs, discontinue drug immediately. No dose adjustment recommended for first trimester use, but consider alternative antihypertensive agent throughout pregnancy.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
ATACAND (candesartan cilexetil) is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation or dose adjustment. Avoid use in pregnancy (Category D). May cause angioedema; discontinue immediately if occurs. Dual blockade with ACE inhibitors or aliskiren increases risk of hypotension, hyperkalemia, and renal impairment.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take ATACAND exactly as prescribed, typically once daily with or without food.,Do not use if pregnant or planning pregnancy; consult doctor immediately if pregnancy occurs.,May cause dizziness or lightheadedness, especially during initial therapy; avoid driving until effects are known.,Avoid potassium supplements or salt substitutes containing potassium unless directed by healthcare provider.,Report signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to physician immediately.,Maintain adequate hydration and avoid dehydration (excessive sweating, vomiting, diarrhea).
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATACAND vs OFIRMEV, answered by our medical review team.
ATACAND is a Angiotensin II Receptor Blocker that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATACAND and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATACAND is: Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATACAND and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATACAND is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, sk. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.